Sunday, August 22, 2010

Covidien to support Positron Corp. in radiopharmaceutical development

Positron Corporation said Thursday it has signed an agreement with Covidien, under which Covidien will provide technical assistance to Positron in connection with Positron’s development of technology to automate the compounding of radiopharmaceuticals.

The agreement combines Covidien’s expertise in radiopharmaceuticals and regulatory issues with Positron’s expertise in automation and radiopharmaceuticals. Automating the distribution of radiopharmaceuticals has many benefits, ranging from worker safety to cost savings to enhanced customer service. 

“Positron continues to provide unique solutions to the molecular imaging community,” said John Zehner, COO of Positron. “This agreement provides Positron with various advantages and additional resources. We are very excited to collaborate with Covidien on this project.”
Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. 

More information about Positron is available at

No comments: